ALKS
Price
$28.82
Change
-$0.08 (-0.28%)
Updated
Jun 26, 04:59 PM (EDT)
Capitalization
4.55B
27 days until earnings call
ESPR
Price
$1.02
Change
+$0.01 (+0.99%)
Updated
Jun 26, 04:59 PM (EDT)
Capitalization
495.94M
40 days until earnings call
Interact to see
Advertisement

ALKS vs ESPR

Header iconALKS vs ESPR Comparison
Open Charts ALKS vs ESPRBanner chart's image
Alkermes
Price$28.82
Change-$0.08 (-0.28%)
Volume$29.26K
Capitalization4.55B
Esperion Therapeutics
Price$1.02
Change+$0.01 (+0.99%)
Volume$58.08K
Capitalization495.94M
ALKS vs ESPR Comparison Chart in %
Loading...
ALKS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ESPR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ALKS vs. ESPR commentary
Jun 27, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALKS is a Buy and ESPR is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 27, 2025
Stock price -- (ALKS: $28.90 vs. ESPR: $1.01)
Brand notoriety: ALKS and ESPR are both not notable
Both companies represent the Pharmaceuticals: Other industry
Current volume relative to the 65-day Moving Average: ALKS: 73% vs. ESPR: 34%
Market capitalization -- ALKS: $4.55B vs. ESPR: $495.94M
ALKS [@Pharmaceuticals: Other] is valued at $4.55B. ESPR’s [@Pharmaceuticals: Other] market capitalization is $495.94M. The market cap for tickers in the [@Pharmaceuticals: Other] industry ranges from $77.48B to $0. The average market capitalization across the [@Pharmaceuticals: Other] industry is $3.78B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ALKS’s FA Score shows that 2 FA rating(s) are green whileESPR’s FA Score has 0 green FA rating(s).

  • ALKS’s FA Score: 2 green, 3 red.
  • ESPR’s FA Score: 0 green, 5 red.
According to our system of comparison, ALKS is a better buy in the long-term than ESPR.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ALKS’s TA Score shows that 3 TA indicator(s) are bullish while ESPR’s TA Score has 5 bullish TA indicator(s).

  • ALKS’s TA Score: 3 bullish, 6 bearish.
  • ESPR’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, ESPR is a better buy in the short-term than ALKS.

Price Growth

ALKS (@Pharmaceuticals: Other) experienced а -1.47% price change this week, while ESPR (@Pharmaceuticals: Other) price change was -8.18% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -0.82%. For the same industry, the average monthly price growth was +13.89%, and the average quarterly price growth was +90.97%.

Reported Earning Dates

ALKS is expected to report earnings on Jul 23, 2025.

ESPR is expected to report earnings on Aug 05, 2025.

Industries' Descriptions

@Pharmaceuticals: Other (-0.82% weekly)

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ALKS($4.55B) has a higher market cap than ESPR($496M). ALKS YTD gains are higher at: 0.487 vs. ESPR (-54.091). ALKS has higher annual earnings (EBITDA): 519M vs. ESPR (-150.11M). ALKS has more cash in the bank: 773M vs. ESPR (82.2M). ESPR has less debt than ALKS: ESPR (266M) vs ALKS (372M). ALKS has higher revenues than ESPR: ALKS (1.66B) vs ESPR (116M).
ALKSESPRALKS / ESPR
Capitalization4.55B496M918%
EBITDA519M-150.11M-346%
Gain YTD0.487-54.091-1%
P/E Ratio8.90N/A-
Revenue1.66B116M1,434%
Total Cash773M82.2M940%
Total Debt372M266M140%
FUNDAMENTALS RATINGS
ALKS vs ESPR: Fundamental Ratings
ALKS
ESPR
OUTLOOK RATING
1..100
6471
VALUATION
overvalued / fair valued / undervalued
1..100
99
Overvalued
36
Fair valued
PROFIT vs RISK RATING
1..100
30100
SMR RATING
1..100
38100
PRICE GROWTH RATING
1..100
5863
P/E GROWTH RATING
1..100
10100
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ESPR's Valuation (36) in the Biotechnology industry is somewhat better than the same rating for ALKS (99). This means that ESPR’s stock grew somewhat faster than ALKS’s over the last 12 months.

ALKS's Profit vs Risk Rating (30) in the Biotechnology industry is significantly better than the same rating for ESPR (100). This means that ALKS’s stock grew significantly faster than ESPR’s over the last 12 months.

ALKS's SMR Rating (38) in the Biotechnology industry is somewhat better than the same rating for ESPR (100). This means that ALKS’s stock grew somewhat faster than ESPR’s over the last 12 months.

ALKS's Price Growth Rating (58) in the Biotechnology industry is in the same range as ESPR (63). This means that ALKS’s stock grew similarly to ESPR’s over the last 12 months.

ALKS's P/E Growth Rating (10) in the Biotechnology industry is significantly better than the same rating for ESPR (100). This means that ALKS’s stock grew significantly faster than ESPR’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ALKSESPR
RSI
ODDS (%)
N/A
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
80%
Momentum
ODDS (%)
Bearish Trend 2 days ago
63%
Bearish Trend 2 days ago
87%
MACD
ODDS (%)
Bearish Trend 2 days ago
61%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
64%
Bearish Trend 2 days ago
90%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
63%
Bullish Trend 2 days ago
83%
Advances
ODDS (%)
Bullish Trend 3 days ago
75%
Bullish Trend 21 days ago
84%
Declines
ODDS (%)
Bearish Trend 7 days ago
63%
Bearish Trend 4 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
76%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
N/A
Bullish Trend 2 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
ALKS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ESPR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
OCLGX13.650.06
+0.44%
Optimum Large Cap Growth C
FLUTX27.42N/A
N/A
Fidelity Advisor Stk Selec Lg Cp Val M
JVAAX38.03N/A
N/A
JPMorgan Value Advantage A
FTZIX53.07N/A
N/A
FullerThaler Behavrl Uncnstd Eq
GCAVX20.23N/A
N/A
GMO US Small Cap Value VI

ALKS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ALKS has been loosely correlated with ESPR. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if ALKS jumps, then ESPR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ALKS
1D Price
Change %
ALKS100%
-1.53%
ESPR - ALKS
35%
Loosely correlated
-5.61%
VTRS - ALKS
34%
Loosely correlated
-0.67%
PAHC - ALKS
34%
Loosely correlated
-0.08%
COLL - ALKS
34%
Loosely correlated
-1.06%
PRGO - ALKS
33%
Poorly correlated
-0.49%
More